Literature DB >> 31327684

Ischemic Stroke Associated With Calcitonin Gene-Related Peptide Inhibitor Therapy for Migraine: A Case Report.

Stephen Aradi1, Eric Kaiser1, Brett Cucchiara2.   

Abstract

Calcitonin gene-related peptide (CGRP) is involved in nociception and neurogenic inflammation in migraine, but also serves as a potent vasodilator acting on intracranial arteries. This latter effect raises concern about the possibility of drugs inhibiting CGRP precipitating cerebral ischemia. We describe a 41-year-old woman with migraine without aura who developed a right thalamic infarction following a first dose of erenumab, a CGRP-receptor blocker. Stroke onset occurred during a typical migraine. Imaging demonsrated right posterior cerebral artery near-occlusion initially with normalization of the vessel at follow-up imaging 2 months later, suggesting vasospasm as a possible mechanism. Extensive evaluation revealed no other specific cause of stroke or vascular risk factors aside from long-term use of oral contraceptive pills. CGRP inhibitors might be associated with ischemic stroke due to blockade of normal cerebral vasodilatory regulatory function.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Migraine; calcitonin gene-related peptide; ischemic stroke; side effects

Year:  2019        PMID: 31327684     DOI: 10.1016/j.jstrokecerebrovasdis.2019.07.002

Source DB:  PubMed          Journal:  J Stroke Cerebrovasc Dis        ISSN: 1052-3057            Impact factor:   2.136


  11 in total

1.  Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting.

Authors:  Anne-Sophie Wattiez; Levi P Sowers; Andrew F Russo
Journal:  Expert Opin Ther Targets       Date:  2020-02-13       Impact factor: 6.902

Review 2.  Real-World Patient Experience of CGRP-Targeting Therapy for Migraine: a Narrative Review.

Authors:  Ann M Murray; Jennifer I Stern; Carrie E Robertson; Chia-Chun Chiang
Journal:  Curr Pain Headache Rep       Date:  2022-09-05

Review 3.  Drug Safety in Episodic Migraine Management in Adults. Part 2: Preventive Treatments.

Authors:  Abigail L Chua; Sandhya Mehla; Yulia Y Orlova
Journal:  Curr Pain Headache Rep       Date:  2022-05-19

4.  The potential danger of blocking CGRP for treating migraine in CADASIL patients.

Authors:  Irene de Boer; Antoinette MaassenVanDenBrink; Gisela M Terwindt
Journal:  Cephalalgia       Date:  2020-07-13       Impact factor: 6.292

5.  Calcitonin gene-related peptide: A biomarker for stroke in SARS-CoV-2 infection?

Authors:  Yassamine Ouerdane; Yahia Khlidj; Mohamed S Attia; Rafik Korissi
Journal:  Med Hypotheses       Date:  2022-02-23       Impact factor: 4.411

Review 6.  Migraine Prevention with Erenumab: Focus on Patient Selection, Perspectives and Outcomes.

Authors:  Eleonora De Matteis; Simona Sacco; Raffaele Ornello
Journal:  Ther Clin Risk Manag       Date:  2022-04-05       Impact factor: 2.423

Review 7.  The Neuropeptide α-Calcitonin Gene-Related Peptide as the Mediator of Beneficial Effects of Exercise in the Cardiovascular System.

Authors:  Tom Skaria; Johannes Vogel
Journal:  Front Physiol       Date:  2022-03-31       Impact factor: 4.566

8.  Editorial: Lifestyle modifications to manage migraine.

Authors:  Yohannes W Woldeamanuel; Surya Shrivastava; Marta Vila-Pueyo
Journal:  Front Neurol       Date:  2022-08-29       Impact factor: 4.086

Review 9.  The Role of Galcanezumab in Migraine Prevention: Existing Data and Future Directions.

Authors:  Panagiotis Gklinos; Dimos D Mitsikostas
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-09

10.  Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis.

Authors:  Lucas Hendrik Overeem; Bianca Raffaelli; Jasper Mecklenburg; Tim Kelderman; Lars Neeb; Uwe Reuter
Journal:  CNS Drugs       Date:  2021-07-16       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.